Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.7
3.6
Journals
ncRNA
Special Issues
Non-coding RNA as Biomarker in Cancer
share announcement

Non-coding RNA as Biomarker in Cancer

A special issue of Non-Coding RNA (ISSN 2311-553X). This special issue belongs to the section "Detection and Biomarkers of Non-Coding RNA".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 2330

Special Issue Editors

Dr. Luca Falzone

E-Mail Website
Guest Editor
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
Interests: molecular oncology; oncogenetics; epigenetics; biomarker discovery; drug resistance; microRNAs
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Daniela Calina

E-Mail Website
Guest Editor
Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
Interests: clinical pharmacy; oncology; biomarkers; experimental pharmacology
Special Issues, Collections and Topics in MDPI journals
Dr. Giuseppe Gattuso

E-Mail Website
Guest Editor
Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy
Interests: epigenetics; biomarker discovery; microRNAs; occupational carcinogens; molecular oncology; cancer; DNA methylation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer represents one of the main causes of death worldwide. Despite the advancement in diagnostic strategies and therapeutic interventions, this pathology is still responsible for millions of deaths annually, highlighting the need for novel diagnostic and prognostic biomarkers for a better management of tumors. In recent decades, several molecular mechanisms that are responsible for the development of tumors have been clarified; however, the precise pathogenetic role that is played by non-coding RNAs has not yet been elucidated. In this context, non-coding RNAs are emerging as novel promising biomarkers in oncology.

Non-coding RNAs, which were previously considered genomic “dark matter”, are now recognized for their intricate regulatory roles in the cellular processes underlying cancer development, as well as for their potential as promising biomarkers in cancer diagnostics and prognostics. Their dysregulation in various cancer types presents an opportunity for precise and early detection, offering insights into the disease progression and therapeutic responses.

On these bases, this Special Issue aims to delve into the significance of non-coding RNAs, such as microRNAs and long non-coding RNAs. Recent advancements and compelling evidence showcasing the utility of non-coding RNAs as accessible and specific biomarkers will be explored, paving the way for enhanced cancer diagnosis and personalized treatment strategies. This journey into the world of non-coding RNAs promises to unravel novel dimensions in the intricate landscape of cancer biomarker research.

Potential topics will include, but are not limited to the following:

  • The role of microRNAs in cancer;
  • The role of long non-coding RNAs in cancer;
  • Liquid biopsies and circulating non-coding RNAs;
  • Non-coding RNAs as diagnostic biomarkers;
  • Non-coding RNAs as prognostic biomarkers;
  • Non-coding RNAs as therapeutic targets in cancer;
  • Epigenetic alterations in cancer and their interplay with ncRNAs;
  • Emerging technologies in ncRNA research, such as next-generation sequencing and CRISPR-Cas systems.

Yours faithfully,

Dr. Luca Falzone
Prof. Dr. Daniela Calina
Dr. Giuseppe Gattuso
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Non-Coding RNA is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer biomarkers
  • non-coding RNAs
  • cancer development
  • epigenetic alterations
  • microRNAs
  • long non-coding RNAs
  • liquid biopsies
  • personalized medicine
  • next-generation sequencing

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

21 pages, 1627 KiB  
Article
High Sensitivity and Specificity Platform to Validate MicroRNA Biomarkers in Cancer and Human Diseases
by Anastassia Kanavarioti, M. Hassaan Rehman, Salma Qureshi, Aleena Rafiq and Madiha Sultan
Non-Coding RNA 2024, 10(4), 42; https://doi.org/10.3390/ncrna10040042 - 22 Jul 2024
Viewed by 1276
Abstract
We developed a technology for detecting and quantifying trace nucleic acids using a bracketing protocol designed to yield a copy number with approximately ± 20% accuracy across all concentrations. The microRNAs (miRNAs) let-7b, miR-15b, miR-21, miR-375 and miR-141 were measured in serum and [...] Read more.
We developed a technology for detecting and quantifying trace nucleic acids using a bracketing protocol designed to yield a copy number with approximately ± 20% accuracy across all concentrations. The microRNAs (miRNAs) let-7b, miR-15b, miR-21, miR-375 and miR-141 were measured in serum and urine samples from healthy subjects and patients with breast, prostate or pancreatic cancer. Detection and quantification were amplification-free and enabled using osmium-tagged probes and MinION, a nanopore array detection device. Combined serum from healthy men (Sigma-Aldrich, St. Louis, MO, USA #H6914) was used as a reference. Total RNA isolated from biospecimens using commercial kits was used as the miRNA source. The unprecedented ± 20% accuracy led to the conclusion that miRNA copy numbers must be normalized to the same RNA content, which in turn illustrates (i) independence from age, sex and ethnicity, as well as (ii) equivalence between serum and urine. miR-21, miR-375 and miR-141 copies in cancers were 1.8-fold overexpressed, exhibited zero overlap with healthy samples and had a p-value of 1.6 × 10−22, tentatively validating each miRNA as a multi-cancer biomarker. miR-15b was confirmed to be cancer-independent, whereas let-7b appeared to be a cancer biomarker for prostate and breast cancer, but not for pancreatic cancer. Full article
(This article belongs to the Special Issue Non-coding RNA as Biomarker in Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

25 pages, 1618 KiB  
Review
Non-Coding RNA as a Biomarker in Lung Cancer
by Chahat Suri, Shashikant Swarnkar, LVKS Bhaskar and Henu Kumar Verma
Non-Coding RNA 2024, 10(5), 50; https://doi.org/10.3390/ncrna10050050 - 30 Sep 2024
Viewed by 544
Abstract
Introduction: Lung cancer remains one of the most prevalent and deadly cancers globally, with high mortality rates largely due to late-stage diagnosis, aggressive progression, and frequent recurrence. Despite advancements in diagnostic techniques and therapeutic interventions, the overall prognosis for lung cancer patients continues [...] Read more.
Introduction: Lung cancer remains one of the most prevalent and deadly cancers globally, with high mortality rates largely due to late-stage diagnosis, aggressive progression, and frequent recurrence. Despite advancements in diagnostic techniques and therapeutic interventions, the overall prognosis for lung cancer patients continues to be dismal. Method: Emerging research has identified non-coding RNAs (ncRNAs), including microRNAs, long non-coding RNAs, and circular RNAs, as critical regulators of gene expression, significantly influencing cancer biology. These ncRNAs play pivotal roles in various aspects of lung cancer pathogenesis, including tumor initiation, progression, metastasis, and resistance to therapy. Results: We provide a comprehensive analysis of the current understanding of ncRNAs in lung cancer, emphasizing their potential as biomarkers for early diagnosis, prognostication, and the prediction of the therapeutic response. We explore the biological functions of ncRNAs, their involvement in key oncogenic pathways, and the molecular mechanisms by which they modulate gene expression and cellular processes in lung cancer. Furthermore, this review highlights recent advances in ncRNA-based diagnostic tools and therapeutic strategies, such as miRNA mimics and inhibitors, lncRNA-targeted therapies, and circRNA-modulating approaches, offering promising avenues for personalized medicine. Conclusion: Finally, we discuss the challenges and future directions in ncRNA research, including the need for large-scale validation studies and the development of efficient delivery systems for ncRNA-based therapies. This review underscores the potential of ncRNAs to revolutionize lung cancer management by providing novel diagnostic and therapeutic options that could improve patient outcomes. Full article
(This article belongs to the Special Issue Non-coding RNA as Biomarker in Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop